Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

NCT03126630 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

49

Enrollment

NIH

Sponsor class

Conditions

Pleural Malignant Mesothelioma

Interventions

BIOLOGICAL: Anetumab Ravtansine
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)